Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, July 12, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced today that the Group has completed IND-enabling studies for STP125G, an siRNA therapeutics targeting Apolipoprotein C3 (ApoC3), based on its proprietary GalAhead™ mxRNA technology....
Smartee Denti-Technology Debuts Themed Airplane with Spring Airlines
SHANGHAI, July 12, 2024 /PRNewswire/ -- Smartee Denti-Technology, in partnership with Spring Airlines, unveiled its inaugural themed airplane at Shanghai Hongqiao International Airport. The event was part of Smartee's 20th-anniversary celebrations. Smartee-themed airplane The Smartee-themed airplane is the centerpiece of the strategic collaboration between both companies. Adorned with the brand logo, its elegant and modern design creates a unique aerial...
CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE
BEIJING, July 12, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it plans to change the ratio of its American depositary shares ("ADSs") to Class A ordinary shares (the "ADS Ratio") from the current ADS Ratio...
Origin Agritech Chairman and CEO Dr. Gengchen Han Provides Business Updates and Answers Questions from Investors
BEIJING, July 11, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, provided a business update from Dr. Gengchen Han, Chairman and CEO of Origin Agritech. Dear Shareholders, We are pleased to provide you with an update on our recent developments, including our progress in GMO commercialization, the performance of...
Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham
Beckham becomes a strategic investor in Prenetics Beckham and Prenetics are co-founding partners for IM8, a new health and wellness brand LOS ANGELES, July 11, 2024 /PRNewswire/ -- Prenetics, (NASDAQ: PRE) a leading health sciences company, is proud to announce that former international footballer, entrepreneur and philanthropist David Beckham has become a strategic investor in the business. Prenetics and...
First Patient Dosed in Phase I Clinical Trial of YOLT-201
SHANGHAI, July 11, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, announced today the successful enrollment of the first patient in the Phase I clinical trial of YOLT-201, its independently developed in vivo gene editing therapy. This marks a significant milestone in the clinical development of this therapeutic candidate....
Newest Version of LifeSphere® Regulatory Platform Allows Organizations to Leverage Latest GenAI Technology
End-to-end functionality helps cut skyrocketing costs of compliance & removes workflow inefficiencies The cloud-based platform demonstrates 50%+ efficiency gains across Regulatory Operations by bringing together data, content, and processes in a single ecosystem. Platform is interoperable with LifeSphere Safety and Quality systems. Organizations have the option to embed LifeSphere NavaX, ArisGlobal's next-gen...
CUHK identifies novel gut microbiome biomarkers to facilitate diagnosis of autism spectrum disorders
Pilot clinical study shows modulation of gut microbiome alleviates anxiety symptoms HONG KONG, July 11, 2024 /PRNewswire/ -- A research team from The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) has conducted a large cohort study among 1,627 children with and without autism spectrum disorder (ASD) and found alterations in four kingdoms of the gut microbial...
Patent rights jointly owned by the National Cancer Center and the University of Pennsylvania, licensed to ARC Therapies, Inc.
Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL) TOKYO, July 11, 2024 /PRNewswire/ -- The National Cancer Center (Tokyo, Japan) and The University of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric antigen receptor T cell therapy that targets the chemokine receptor CCR4 (CCR4 CAR-T cell therapy) to...
Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL)
Patent rights jointly owned by the National Cancer Center and the University of Pennsylvania, licensed to ARC Therapies, Inc. TOKYO, July 11, 2024 /PRNewswire/ -- The National Cancer Center (Tokyo, Japan) and The University of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric antigen receptor T cell therapy that targets the chemokine receptor CCR4 (CCR4...
